A Phase Ib Study of NVX-508 in Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03013426

Recruitment Status : Withdrawn (NuvOx Pharma suspended the clinical program related to this study.)

First Posted : January 6, 2017

Last Update Posted : July 16, 2018

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

NuvOx LLC

Noguchi Memorial Institute for Medical Research

Information provided by (Responsible Party):

Amma Owusu-Ansah, MD, University of Pittsburgh

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Withdrawn
Estimated Primary Completion Date :	December 2018
Estimated Study Completion Date :	December 2018

Publications:

Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008 Jun;86(6):480-7. doi: 10.2471/blt.06.036673.

Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011 Dec;41(6 Suppl 4):S398-405. doi: 10.1016/j.amepre.2011.09.013.

Johnson JL, Dolezal MC, Kerschen A, Matsunaga TO, Unger EC. In vitro comparison of dodecafluoropentane (DDFP), perfluorodecalin (PFD), and perfluoroctylbromide (PFOB) in the facilitation of oxygen exchange. Artif Cells Blood Substit Immobil Biotechnol. 2009;37(4):156-62. doi: 10.1080/10731190903043192. Epub 2009 Jun 22.

Riess JG. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol. 2005;33(1):47-63. doi: 10.1081/bio-200046659.

Grayburn PA, Weiss JL, Hack TC, Klodas E, Raichlen JS, Vannan MA, Klein AL, Kitzman DW, Chrysant SG, Cohen JL, Abrahamson D, Foster E, Perez JE, Aurigemma GP, Panza JA, Picard MH, Byrd BF 3rd, Segar DS, Jacobson SA, Sahn DJ, DeMaria AN. Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms. J Am Coll Cardiol. 1998 Jul;32(1):230-6. doi: 10.1016/s0735-1097(98)00219-8.

Correas JM, Meuter AR, Singlas E, Kessler DR, Worah D, Quay SC. Human pharmacokinetics of a perfluorocarbon ultrasound contrast agent evaluated with gas chromatography. Ultrasound Med Biol. 2001 Apr;27(4):565-70. doi: 10.1016/s0301-5629(00)00363-x.

To Top